Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | PIK3CA E545K |
Therapy | Inavolisib |
Indication/Tumor Type | breast cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA E545K | breast cancer | sensitive | Inavolisib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Itovebi (inavolisib) treatment led to tumor regression in an ESR1 (ER)-positive breast cancer cell line xenograft model harboring PIK3CA E545K (PMID: 34544753). | 34544753 |
PubMed Id | Reference Title | Details |
---|---|---|
(34544753) | RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy. | Full reference... |